KR102525091B1 - A cosmetic compositon for pore-minimizing comprising natural complex extract as an active ingredient - Google Patents
A cosmetic compositon for pore-minimizing comprising natural complex extract as an active ingredient Download PDFInfo
- Publication number
- KR102525091B1 KR102525091B1 KR1020230038542A KR20230038542A KR102525091B1 KR 102525091 B1 KR102525091 B1 KR 102525091B1 KR 1020230038542 A KR1020230038542 A KR 1020230038542A KR 20230038542 A KR20230038542 A KR 20230038542A KR 102525091 B1 KR102525091 B1 KR 102525091B1
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- apple
- activity
- skin
- cosmetic composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000284 extract Substances 0.000 title claims abstract description 158
- 239000002537 cosmetic Substances 0.000 title claims abstract description 62
- 239000004480 active ingredient Substances 0.000 title claims abstract description 15
- 239000006227 byproduct Substances 0.000 claims abstract description 59
- 239000000203 mixture Substances 0.000 claims abstract description 55
- 239000011148 porous material Substances 0.000 claims abstract description 50
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 51
- 238000000605 extraction Methods 0.000 claims description 34
- 239000002904 solvent Substances 0.000 claims description 33
- 244000236655 Diospyros kaki Species 0.000 claims description 30
- 235000011511 Diospyros Nutrition 0.000 claims description 29
- 230000037394 skin elasticity Effects 0.000 claims description 20
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 15
- 230000003078 antioxidant effect Effects 0.000 claims description 15
- 230000009467 reduction Effects 0.000 claims description 8
- 239000003963 antioxidant agent Substances 0.000 claims description 7
- 230000000052 comparative effect Effects 0.000 description 111
- 241000220225 Malus Species 0.000 description 77
- 230000000694 effects Effects 0.000 description 57
- 210000003491 skin Anatomy 0.000 description 55
- 230000006872 improvement Effects 0.000 description 29
- 210000004027 cell Anatomy 0.000 description 20
- 238000004519 manufacturing process Methods 0.000 description 20
- 230000002195 synergetic effect Effects 0.000 description 15
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 14
- 239000002131 composite material Substances 0.000 description 14
- 230000008859 change Effects 0.000 description 13
- 238000002156 mixing Methods 0.000 description 13
- 239000002994 raw material Substances 0.000 description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 230000003712 anti-aging effect Effects 0.000 description 12
- 239000006071 cream Substances 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 11
- 239000006228 supernatant Substances 0.000 description 10
- 229910002091 carbon monoxide Inorganic materials 0.000 description 9
- 230000007423 decrease Effects 0.000 description 9
- 210000002950 fibroblast Anatomy 0.000 description 9
- -1 quercetin glycoside Chemical class 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 102000008186 Collagen Human genes 0.000 description 8
- 108010035532 Collagen Proteins 0.000 description 8
- 229920001436 collagen Polymers 0.000 description 8
- 238000002835 absorbance Methods 0.000 description 7
- 230000009471 action Effects 0.000 description 7
- 239000006210 lotion Substances 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 6
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 6
- 102000016387 Pancreatic elastase Human genes 0.000 description 6
- 108010067372 Pancreatic elastase Proteins 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 235000006708 antioxidants Nutrition 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 102000016942 Elastin Human genes 0.000 description 5
- 108010014258 Elastin Proteins 0.000 description 5
- 230000032683 aging Effects 0.000 description 5
- 229920002549 elastin Polymers 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 239000007921 spray Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 230000008602 contraction Effects 0.000 description 4
- 210000004748 cultured cell Anatomy 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 230000002849 elastaseinhibitory effect Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 241001070941 Castanea Species 0.000 description 3
- 235000014036 Castanea Nutrition 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 235000021016 apples Nutrition 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 3
- 229960003957 dexamethasone Drugs 0.000 description 3
- 210000004177 elastic tissue Anatomy 0.000 description 3
- 230000001815 facial effect Effects 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 230000007760 free radical scavenging Effects 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 235000003642 hunger Nutrition 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000003642 reactive oxygen metabolite Substances 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- JUJBNYBVVQSIOU-UHFFFAOYSA-M sodium;4-[2-(4-iodophenyl)-3-(4-nitrophenyl)tetrazol-2-ium-5-yl]benzene-1,3-disulfonate Chemical compound [Na+].C1=CC([N+](=O)[O-])=CC=C1N1[N+](C=2C=CC(I)=CC=2)=NC(C=2C(=CC(=CC=2)S([O-])(=O)=O)S([O-])(=O)=O)=N1 JUJBNYBVVQSIOU-UHFFFAOYSA-M 0.000 description 3
- 230000037351 starvation Effects 0.000 description 3
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 239000002211 L-ascorbic acid Substances 0.000 description 2
- 235000000069 L-ascorbic acid Nutrition 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 2
- 235000005487 catechin Nutrition 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 229950001002 cianidanol Drugs 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000000686 essence Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 229940074391 gallic acid Drugs 0.000 description 2
- 235000004515 gallic acid Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 229930182470 glycoside Natural products 0.000 description 2
- 210000004209 hair Anatomy 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 238000010899 nucleation Methods 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 239000012679 serum free medium Substances 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- NNDIXBJHNLFJJP-UHFFFAOYSA-N 20-Hydroxyeicosatetraenoic acid Chemical compound OCCCCCC=CCC=CCC=CCC=CCCCC(O)=O NNDIXBJHNLFJJP-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 101800004538 Bradykinin Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 244000209117 Castanea crenata Species 0.000 description 1
- 235000003801 Castanea crenata Nutrition 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 235000008597 Diospyros kaki Nutrition 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 241000219428 Fagaceae Species 0.000 description 1
- 108060003393 Granulin Proteins 0.000 description 1
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
- 229920002488 Hemicellulose Polymers 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 102100035792 Kininogen-1 Human genes 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- 230000010757 Reduction Activity Effects 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 235000010724 Wisteria floribunda Nutrition 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 238000011481 absorbance measurement Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000003679 aging effect Effects 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 235000010208 anthocyanin Nutrition 0.000 description 1
- 229930002877 anthocyanin Natural products 0.000 description 1
- 239000004410 anthocyanin Substances 0.000 description 1
- 150000004636 anthocyanins Chemical class 0.000 description 1
- 235000015197 apple juice Nutrition 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000008406 cosmetic ingredient Substances 0.000 description 1
- 239000008341 cosmetic lotion Substances 0.000 description 1
- 238000002316 cosmetic surgery Methods 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000004042 decolorization Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000002440 industrial waste Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical class OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 231100000028 nontoxic concentration Toxicity 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 210000001328 optic nerve Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- REFJWTPEDVJJIY-UHFFFAOYSA-N quercetin Natural products C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 238000011076 safety test Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 230000008491 skin homeostasis Effects 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
- A61K2800/24—Thermal properties
- A61K2800/244—Endothermic; Cooling; Cooling sensation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
- A61K2800/522—Antioxidants; Radical scavengers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
본 발명은 모공 수축용 화장료 조성물에 관한 것으로, 사과 부산물 추출물; 및 율피 추출물;을 유효성분으로 포함하는 화장료 조성물을 제공한다.The present invention relates to a cosmetic composition for shrinking pores, comprising: an apple by-product extract; And yulpi extract; It provides a cosmetic composition containing as an active ingredient.
Description
본 발명은 천연 복합 추출물을 유효성분으로 포함하는 화장료 조성물에 조성물에 관한 것으로, 복합 성분의 시너지 활성을 통해 우수한 피부 개선 효과를 구현할 수 있다.The present invention relates to a cosmetic composition comprising a natural composite extract as an active ingredient, and can realize excellent skin improvement effects through synergistic activity of the composite components.
현대 사회에서 인간의 외모를 가꾸는 데에 대한 관심은 갈수록 높아지고 있으며, 화장품, 화장 기술, 성형수술, 헤어, 의상, 악세서리 등과 같은 다양한 분야에서 산업화되어 있다.In modern society, interest in improving human appearance is increasing, and various fields such as cosmetics, makeup technology, plastic surgery, hair, clothing, and accessories are industrialized.
외모에 대한 관심 속에서 깨끗한 피부는 외모를 아름답게 보이게 하는 중요한 요소 중 하나이며, 피부의 미용적 개선을 위하여 피부의 노화를 예방하거나 치료하는 기능성 화장품 및 피부의 모공을 축소시키는 효과를 갖는 화장품이 널리 소비되고 있다.In the interest in appearance, clean skin is one of the important factors that make the appearance beautiful, and functional cosmetics that prevent or treat aging of the skin and cosmetics that have the effect of reducing skin pores are widely used for cosmetic improvement of the skin. are being consumed
최근 천연물 등으로부터 얻은 생리 활성 물질을 화장료에 도입하여 친환경 특성의 기능성 화장품 개발이 활발하게 진행되는 추세이다.Recently, the development of eco-friendly functional cosmetics by introducing physiologically active substances obtained from natural products into cosmetics is actively progressing.
그리고, 피부의 미용적 개선을 위하여 피부의 노화를 예방하거나 치료하는 기능성 화장품 및 피부의 모공을 축소시키는 효과를 갖는 화장품 또는 식품 소재들이 남녀노소를 불문하고 넓게 소비되고 있다. In addition, functional cosmetics that prevent or treat aging of the skin for cosmetic improvement of the skin and cosmetics or food materials having an effect of reducing skin pores are widely consumed regardless of age or gender.
모공이란 피지선에서 분비되는 유분이 피부 표면으로 흘러나오는 작은 구멍으로, 털이 자라나는 입구를 말한다. 피부에는cm2당 100 내지 120개의 모공이 존재하여 사람의 얼굴에는 약 2만개의 모공이 있다. A pore is a small hole through which oil secreted by the sebaceous gland flows out to the surface of the skin, and refers to the entrance through which hair grows. There are 100 to 120 pores per cm 2 in the skin, and there are about 20,000 pores in the human face.
일반적으로 모공의 지름은 약 0.02 내지 0.05mm로 매우 작아 보통 눈에 잘 띄지 않으나 나이, 계절, 여성의 생리주기, 임신, 스트레스 등에 의해 피지 분비가 과다해지면 육안으로 확인할 수 있을 정도로 커지고, 모공이 넓은 피부는 미용상 부정적인 이미지를 야기할 수 있다. In general, pores have a diameter of about 0.02 to 0.05 mm, which is very small and usually not noticeable. Skin can cause a negative cosmetic image.
모공이 열려 있으면 모낭 내로 세균이 침입하기 용이해지며, 피부 트러블을 일으키기 쉬우므로, 화장품을 이용한 모공의 관리는 매우 중요하다. 모공이 확장되는 원인에는 피지 과다분비, 피부 노화, 모공 속 노폐물 축적 등이 있다. If the pores are open, it is easy for bacteria to enter the hair follicles, and it is easy to cause skin troubles, so it is very important to manage the pores using cosmetics. The causes of enlarged pores include excessive secretion of sebum, aging of the skin, and accumulation of wastes in the pores.
피부의 탄력이 저하되면 모공 벽을 지지하던 콜라겐과 탄력섬유가 점차 감소하고, 모공을 조여주는 힘이 떨어지기 때문에 모공이 늘어나게 된다.When the elasticity of the skin decreases, the collagen and elastic fibers that support the pore walls gradually decrease, and the force to tighten the pores decreases, resulting in enlarged pores.
통상적으로 20대 후반부터 모공이 커지게 되는데, 피부가 노화되면서 각질형성세포(keratinocyte)와 섬유아세포(fibroblast)의 활성이 감소하게 되고, 콜라겐 합성능력 및 엘라스틴 합성능력이 감소하고, 수분보유능력이 감소하면서 피부의 탄력이 줄어들어 모공이 커지게 된다.Normally, pores begin to enlarge from the late 20s. As the skin ages, the activity of keratinocytes and fibroblasts decreases, the ability to synthesize collagen and elastin decreases, and the ability to retain moisture decreases. As it decreases, the elasticity of the skin decreases, leading to enlarged pores.
한편, 화장품 업계는 여러 화학물질 등에 의한 피부 자극을 줄이기 위해 천연물을 사용한 다수의 제품을 개발하고 있다. Meanwhile, the cosmetics industry is developing a number of products using natural products to reduce skin irritation caused by various chemicals.
천연 재료는 피부에 부작용이 적을 뿐 아니라, 최근 천연 재료를 이용한 화장품에 대한 소비자들의 호응이 높아짐에 따라 화장품 원료로서 개발가치가 점차 증가하고 있다.Natural materials not only have few side effects on the skin, but also the value of development as a raw material for cosmetics is gradually increasing as consumers' response to cosmetics using natural materials has recently increased.
이러한 배경 하에서, 본 발명자들은 피부 개선을 위한 천연 성분에 관하여 다양한 연구를 수행하였으며, 소정의 복합 추출물의 조합이 피부 탄력 개선, 항염증, 항산화, 항노화 및 모공축소 활성에 있어서 우수한 효과를 나타냄을 규명하여, 본 발명을 완성하게 되었다.Under this background, the present inventors have conducted various studies on natural ingredients for skin improvement, and found that a combination of certain complex extracts exhibits excellent effects in improving skin elasticity, anti-inflammatory, antioxidant, anti-aging and pore-reducing activity. By clarifying, the present invention was completed.
본 발명은 전술한 문제점을 해결하기 위한 것으로, 본 발명의 목적은 피부 안전성이 검증된 원료를 통해 피부 개선 활성을 규명하고, 이를 통해 기능성과 함께 생체 안전성이 우수한 화장료 조성물을 제공하는 것이다.The present invention is to solve the above problems, and an object of the present invention is to identify skin improvement activity through raw materials whose skin safety has been verified, and to provide a cosmetic composition with excellent biosafety as well as functionality through this.
본 발명의 일 측면에 따르면, 사과 부산물 추출물; 및 율피 추출물;을 유효성분으로 포함하는 모공 수축용 화장료 조성물이 제공된다.According to one aspect of the invention, apple by-product extract; And yulpi extract; provided with a cosmetic composition for shrinking pores containing as an active ingredient.
일 실시예에 있어서, 상기 화장료 조성물은 상기 사과 부산물 추출물 50 중량부 및 상기 율피 추출물 30 내지 40 중량부를 포함할 수 있다.In one embodiment, the cosmetic composition may include 50 parts by weight of the apple by-product extract and 30 to 40 parts by weight of the yulpi extract.
일 실시예에 있어서, 상기 화장료 조성물은 감나무잎 추출물;을 더 포함할 수 있다.In one embodiment, the cosmetic composition may further include; persimmon leaf extract.
일 실시예에 있어서, 상기 화장료 조성물은 상기 사과 부산물 추출물 50 중량부, 상기 율피 추출물 30 내지 40 중량부, 및 상기 감나무잎 추출물 10 내지 20 중량부를 포함할 수 있다.In one embodiment, the cosmetic composition may include 50 parts by weight of the apple by-product extract, 30 to 40 parts by weight of the yulpi extract, and 10 to 20 parts by weight of the persimmon leaf extract.
일 실시예에 있어서, 상기 추출물은 60 내지 80%(v/v) 농도의 에탄올을 추출 용매로 하여 수득할 수 있다.In one embodiment, the extract can be obtained by using ethanol at a concentration of 60 to 80% (v / v) as an extraction solvent.
일 실시예에 있어서, 상기 화장료 조성물은 항산화 또는 항염증 용도를 더 포함할 수 있다.In one embodiment, the cosmetic composition may further include antioxidant or anti-inflammatory applications.
일 실시예에 있어서, 상기 화장료 조성물은 피부 탄력 개선 또는 항노화 용도를 더 포함할 수 있다.In one embodiment, the cosmetic composition may further include skin elasticity improvement or anti-aging purposes.
일 실시예에 있어서, 상기 화장료 조성물은 피부 온도 감소 용도를 더 포함할 수 있다.In one embodiment, the cosmetic composition may further include a skin temperature reduction application.
본 발명에 따르면, 상기 화장료 조성물은 피부 모공 축소 효과 등 피부 개선 효과가 뛰어나며, 인체 안전성이 우수하다.According to the present invention, the cosmetic composition has excellent skin improvement effects such as skin pore shrinking effect, and excellent human safety.
본 발명의 효과는 상기한 효과로 한정되는 것은 아니며, 본 발명의 상세한 설명 또는 특허청구범위에 기재된 발명의 구성으로부터 추론 가능한 모든 효과를 포함하는 것으로 이해되어야 한다.The effects of the present invention are not limited to the above effects, and should be understood to include all effects that can be inferred from the detailed description of the present invention or the configuration of the invention described in the claims.
도 1은 본 발명의 일 실시예에 복합 추출물(실시예 10) 적용에 따른 모공 상태의 변화를 촬영한 것이다.
도 2는 본 발명의 일 실시예에 복합 추출물(실시예 10) 적용에 모공 부위 치밀도의 변화를 확인한 것이다.
도 3은 본 발명의 일 실시예에 복합 추출물(실시예 10)의 항산화 활성을 평가한 결과이다.
도 4는 본 발명의 일 실시예에 복합 추출물(실시예 10)의 항염 활성을 평가한 결과이다.
도 5는 본 발명의 일 실시예에 복합 추출물(실시예 10)의 엘라스타제 억제 활성을 평가한 결과이다.
도 6은 본 발명의 일 실시예에 복합 추출물(실시예 10)의 항노화 활성을 평가한 결과이다.Figure 1 is a photograph of the change in the pore state according to the application of the complex extract (Example 10) to one embodiment of the present invention.
Figure 2 confirms the change in pore density in the application of the composite extract (Example 10) to one embodiment of the present invention.
Figure 3 is a result of evaluating the antioxidant activity of the composite extract (Example 10) in one embodiment of the present invention.
Figure 4 is a result of evaluating the anti-inflammatory activity of the composite extract (Example 10) in one embodiment of the present invention.
Figure 5 is the result of evaluating the elastase inhibitory activity of the composite extract (Example 10) in one embodiment of the present invention.
Figure 6 is a result of evaluating the anti-aging activity of the composite extract (Example 10) in one embodiment of the present invention.
본 명세서에서 사용되는 용어는 본 발명에서의 기능을 고려하면서 가능한 현재 널리 사용되는 일반적인 용어들을 선택하였으나, 이는 당 분야에 종사하는 기술자의 의도 또는 판례, 새로운 기술의 출현 등에 따라 달라질 수 있다. 또한, 특정한 경우는 출원인이 임의로 선정한 용어도 있으며, 이 경우 해당되는 발명의 설명 부분에서 상세히 그 의미를 기재할 것이다. 따라서 본 발명에서 사용되는 용어는 단순한 용어의 명칭이 아닌, 그 용어가 가지는 의미와 본 발명의 전반에 걸친 내용을 토대로 정의되어야 한다.The terms used in this specification have been selected from general terms that are currently widely used as much as possible while considering the functions in the present invention, but these may vary depending on the intention of a person skilled in the art, precedent, or the emergence of new technologies. In addition, in a specific case, there is also a term arbitrarily selected by the applicant, and in this case, the meaning will be described in detail in the description of the invention. Therefore, the term used in the present invention should be defined based on the meaning of the term and the overall content of the present invention, not simply the name of the term.
다르게 정의되지 않는 한, 기술적이거나 과학적인 용어를 포함해서 여기서 사용되는 모든 용어들은 본 발명이 속하는 기술 분야에서 통상의 지식을 가진 자에 의해 일반적으로 이해되는 것과 동일한 의미를 가지고 있다. 일반적으로 사용되는 사전에 정의되어 있는 것과 같은 용어들은 관련 기술의 문맥상 가지는 의미와 일치하는 의미를 가지는 것으로 해석되어야 하며, 본 출원에서 명백하게 정의하지 않는 한, 이상적이거나 과도하게 형식적인 의미로 해석되지 않는다.Unless defined otherwise, all terms used herein, including technical or scientific terms, have the same meaning as commonly understood by one of ordinary skill in the art to which the present invention belongs. Terms such as those defined in commonly used dictionaries should be interpreted as having a meaning consistent with the meaning in the context of the related art, and unless explicitly defined in this application, it should not be interpreted in an ideal or excessively formal meaning. don't
수치 범위는 상기 범위에 정의된 수치를 포함한다. 본 명세서에 걸쳐 주어진 모든 최대의 수치 제한은 낮은 수치 제한이 명확히 쓰여져 있는 것처럼 모든 더 낮은 수치 제한을 포함한다. 본 명세서에 걸쳐 주어진 모든 최소의 수치 제한은 더 높은 수치 제한이 명확히 쓰여져 있는 것처럼 모든 더 높은 수치 제한을 포함한다. 본 명세서에 걸쳐 주어진 모든 수치 제한은 더 좁은 수치 제한이 명확히 쓰여져 있는 것처럼, 더 넓은 수치 범위 내의 더 좋은 모든 수치 범위를 포함할 것이다.Numerical ranges are inclusive of the values defined therein. Every maximum numerical limitation given throughout this specification includes every lower numerical limitation, as if such lower numerical limitations were expressly written. Every minimum numerical limitation given throughout this specification includes every higher numerical limitation, as if such higher numerical limitations were expressly written. Every numerical limitation given throughout this specification will include every better numerical range within the broader numerical range, as if the narrower numerical limitations were expressly written.
이하, 본 발명의 실시예를 상세히 기술하나, 하기 실시예에 의해 본 발명이 한정되지 아니함은 자명하다.Hereinafter, embodiments of the present invention will be described in detail, but it is obvious that the present invention is not limited by the following examples.
본 발명의 일 측면은 사과 부산물 추출물; 및 율피 추출물;을 유효성분으로 포함하는 모공 수축용 화장료 조성물을 제공한다.One aspect of the present invention is an apple by-product extract; And yulpi extract; provides a cosmetic composition for shrinking pores containing as an active ingredient.
본 발명자는 상기 사과 부산물 추출물 및 율피 추출물은 독립적으로 작용할 때 보다 동시에 작용할 때 현저하게 우수한 피부 개선 활성을 나타낼 수 있음을 규명하였으며, 상기 화장료 조성물은 유효성분의 시너지 활성을 통해 우수한 피부 개선 효과를 나타낼 수 있다.The present inventors have found that the apple by-product extract and yulpi extract can exhibit significantly superior skin improvement activity when acting simultaneously rather than when acting independently, and the cosmetic composition exhibits excellent skin improvement effect through synergistic activity of active ingredients can
특히, 상기 사과 부산물 추출물은 모공 수축 관련 소재로서 연구된 바 있으나, 율피 추출물과 조합에 의해 관련 피부 활성이 현저히 개선될 수 있음은 규명된 바 없다.In particular, the apple by-product extract has been studied as a material related to pore contraction, but it has not been clarified that the related skin activity can be significantly improved by combination with Yulpi extract.
상기 “유효성분으로 포함하는”은 피부 개선 효과를 나타낼 수 있는, 예컨대, 모공 수축 활성, 항노화 활성과 관련된 콜라겐 합성, 항염 활성 등을 나타낼 수 있는 정도의 유효량을 함유하는 것을 의미할 수 있다.The "contained as an active ingredient" may mean containing an effective amount capable of exhibiting skin improvement effects, such as pore contraction activity, collagen synthesis related to anti-aging activity, anti-inflammatory activity, and the like.
상기 “사과 부산물”은 사과를 원료로 한 사과주스 등의 가공처리 후에 다량 발생하는 사과피 및 사과박을 지칭하는 것으로, 일부는 동물 사료로 사용되지만 대부분이 산업 폐기물로 처리되고 있다.The "apple by-product" refers to apple peel and apple peel, which are generated in large quantities after processing apple juice, etc., using apples as raw materials. Some of them are used as animal feed, but most of them are treated as industrial waste.
상기 사과를 가공한 후 생성되는 사과 부산물들은 난폐기성 물질로서 환경오염의 원인이 되고 있으나, 사과 부산물은 항산화 능력이 뛰어난 퀘르세틴 글리코시드(quercetin glycoside), 시아니디안 글리코시드(cyanidian glycosides) 등의 생리활성물질이 함유되어 있다.Apple by-products produced after processing the apples are intractable substances that cause environmental pollution, but apple by-products have excellent antioxidant capacity, such as quercetin glycoside and cyanidian glycosides. Contains bioactive substances.
특히, 상기 사과 부산물은 셀룰로오스, 헤미셀룰로오스, 펙틴, 미네랄, 폴리페놀, 안토시아닌 등 다당류 및 생리활성물질을 포함하고 있으며, 본 발명자들은 사과의 과육을 이용한 추출물 보다 사과 부산물인 사과박 및 사과피를 원료로 하여 수득한 추출물이 율피 추출물과 함께 작용함으로써 더욱 우수한 모공 축소 활성을 나타낼 수 있음을 확인하였다.In particular, the apple by-products include polysaccharides and physiologically active substances such as cellulose, hemicellulose, pectin, minerals, polyphenols, and anthocyanins, and the present inventors use apple peel and apple peel, which are apple by-products, as raw materials rather than an extract using apple pulp. It was confirmed that the obtained extract can exhibit a more excellent pore-reducing activity by acting together with the yulpi extract.
상기 사과 부산물은 골든 딜리셔스, 레드 딜리셔스, 갈라, 엠파이어, 후지, 매킨토시, 그래니 스미스 및 코틀랜드 등 다양한 품종의 사과로부터 수득할 수 있으나, 바람직하게는 사과 과피 및 사과박으로 이루어진 부산물일 수 있다.The apple by-product may be obtained from apples of various varieties, such as Golden Delicious, Red Delicious, Gala, Empire, Fuji, Macintosh, Granny Smith, and Cortland, but may preferably be a by-product consisting of apple skin and apple peel.
상기 “율피(chestnut inner shell)”는 참나무과(Fagaceae)에 속하는 낙엽 활엽 교목인 밤나무(Castanea crenata Sieb)의 과실인 밤의 속껍질로 밤의 가공공정 중에 대부분 폐기되고 있으나, 율피 내에는 탄닌산(tannic acid), 갈릭산(gallic acid), 카테킨(catechin) 등 유용 성분이 다량 함유되어 있어 이를 산업적으로 활용하기 위한 방안이 논의되고 있다.The “chestnut inner shell” is the inner shell of chestnut, which is the fruit of Castanea crenata Sieb, a deciduous tree belonging to the Fagaceae family , and is mostly discarded during the processing of chestnuts. ), gallic acid (gallic acid), catechin (catechin), etc. contains a large amount of useful components, so plans to use them industrially are being discussed.
일 실시예에서, 상기 화장료 조성물은 상기 사과 부산물 추출물 50 중량부 및 상기 율피 추출물 30 내지 40 중량부를 포함할 수 있다.In one embodiment, the cosmetic composition may include 50 parts by weight of the apple by-product extract and 30 to 40 parts by weight of the yulpi extract.
본 발명자는 다양한 실험을 통해 상기 복합 추출물의 최적 혼합 비율을 도출하였으며, 상기 범위 내에서 상기 조성물의 피부 개선 활성이 극대화될 수 있다. The present inventors have derived the optimal mixing ratio of the complex extract through various experiments, and the skin improvement activity of the composition can be maximized within the above range.
상기 복합 추출물은 사과 부산물 추출물의 비율이 소정의 범위에서 상대적으로 높을 때 시너지 활성이 극대화될 수 있는데, 상기 혼합비가 상기 범위를 크게 벗어나는 경우 각 추출물의 유효성분에서 유래한 피부 개선 효과가 적절하게 구현되지 않을 수 있으므로, 작업 환경 및 최종 산물의 품질을 고려하여 혼합 비율을 적절하게 제어할 수 있다.In the complex extract, synergistic activity can be maximized when the ratio of the apple by-product extract is relatively high within a predetermined range. When the mixing ratio greatly deviate from the above range, the skin improvement effect derived from the active ingredient of each extract is appropriately implemented. Therefore, the mixing ratio can be appropriately controlled in consideration of the working environment and the quality of the final product.
상기 화장료 조성물은 감나무잎 추출물;을 더 포함할 수 있다.The cosmetic composition may further include a persimmon leaf extract.
상기 "감나무잎"은 감나무목 감나무과의 낙엽활엽 교목인 감나무(Diospyros kaki)의 잎을 의미하며, 상기 감나무잎 함유되어 있는 유기산과 카페인은 피로회복과 각성효과가 있으며, 혈당 강하, 혈액순환 장애, 대사성 장애, 면역 증강, 시신경 보호 등의 약리 활성을 가지는 것으로 알려진 바 있다.The "persimmon leaf" refers to the leaves of the persimmon tree ( Diospyros kaki ), a deciduous tree of the persimmon tree persimmon family, and the organic acid and caffeine contained in the persimmon tree leaves have fatigue recovery and awakening effects, lowering blood sugar, blood circulation disorders, It is known to have pharmacological activities such as metabolic disorders, immune enhancement, and optic nerve protection.
상기 감나무잎 추출물이 상기 사과 부산물 추출물 및 율피 추출물과 함께 작용함으로써 더욱 우수한 피부 개선 활성을 나타낼 수 있다.The persimmon leaf extract may exhibit more excellent skin improvement activity by acting together with the apple by-product extract and the yulpi extract.
이 때, 상기 화장료 조성물은 상기 사과 부산물 추출물 50 중량부, 상기 율피 추출물 30 내지 40 중량부, 및 상기 감나무잎 추출물 10 내지 20 중량부를 포함할 수 있다.At this time, the cosmetic composition may include 50 parts by weight of the apple by-product extract, 30 to 40 parts by weight of the yulpi extract, and 10 to 20 parts by weight of the persimmon leaf extract.
상기 감나무잎 추출물은 상기 사과 부산물 추출물 및 율피 추출물과 소정의 혼합 비율 내에서 모공 수축 활성이 극대화될 수 있으며 상기 범위를 벗어나는 경우 피부 개선 활성이 저하될 수 있으므로, 상기 복합 추출물의 혼합 비율을 적절히 제어하는 것이 바람직하다.The persimmon leaf extract can maximize the pore shrinking activity within a predetermined mixing ratio with the apple by-product extract and the yulpi extract, and the skin improvement activity may decrease when it is out of the above range. Appropriately control the mixing ratio of the complex extract It is desirable to do
상기 “추출물”은 용매와 추출 원료를 특정 조건하에서 접촉시킴으로써 추출 원료에 함유된 유효성분을 분리해낸 것으로, 상기 추출물은 추출 원료에 함유된 다양한 유효성분을 포함할 수 있다.The "extract" is obtained by separating the active ingredient contained in the extraction material by contacting the solvent and the extraction material under specific conditions, and the extract may include various active ingredients contained in the extraction material.
상기 추출물을 수득하는 방법은 특별히 제한되지 않고, 용매를 사용하여 냉침, 온침, 가열 등 당해 기술 분야의 통상적인 방법을 통해 수득할 수 있으며, 예컨대, 천연 원료를 용매에 투입하고 가열하여 수득할 수 있다.The method for obtaining the extract is not particularly limited, and may be obtained through a conventional method in the art, such as cooling, warming, and heating using a solvent. For example, it may be obtained by introducing a natural raw material into a solvent and heating it. there is.
구체적으로, 상기 추출물은 추출 원료를 물로 수세한 후 건조시키고 잘게 분쇄하여, 각 원료 중량의 5 내지 20배에 달하는 부피의 용매로 약 2시간 내지 5시간 동안 환류 순환 추출, 가압 추출, 초음파 추출 등의 통상적인 방법으로 추출하고 여과함으로써 제조될 수 있다.Specifically, the extract is obtained by washing the extraction raw materials with water, drying them, and finely pulverizing them, reflux circulation extraction, pressurized extraction, ultrasonic extraction, etc. It can be prepared by extracting and filtering by a conventional method of.
또한, 상기 추출물은 감압 증류 또는 동결 건조 등과 같은 추가적인 공정에 의해 분말 상태로 수득될 수 있다.In addition, the extract may be obtained in a powder state by an additional process such as distillation under reduced pressure or freeze drying.
상기 추출물은 통상적인 정제 과정을 거친 추출물도 포함할 수 있다. 예컨대, 상기 추출물은 일정한 분자량 컷-오프 값을 갖는 한외 여과막을 이용한 분리, 다양한 크로마토그래피(크기, 전하, 소수성 또는 친화성에 따른 분리를 위해 제작된 것)에 의한 분리 등 추가적으로 실시된 다양한 정제 방법을 통해 얻어진 분획물을 포함할 수 있다.The extract may also include an extract that has undergone a conventional purification process. For example, the extract is subjected to various additional purification methods such as separation using an ultrafiltration membrane having a certain molecular weight cut-off value and separation by various chromatography (made for separation according to size, charge, hydrophobicity or affinity). It may include fractions obtained through
상기 추출 공정에 있어서 용매의 종류는 특별히 한정되지 않으며 필요에 따라 다양한 용매를 사용할 수 있으나 바람직하게는 상기 추출물은 60 내지 80%(v/v) 농도의 에탄올을 추출 용매로 하여 수득할 수 있다.In the extraction process, the type of solvent is not particularly limited, and various solvents may be used as necessary, but preferably, the extract may be obtained by using ethanol at a concentration of 60 to 80% (v / v) as an extraction solvent.
상기 원료에 포함된 유효성분은 용매의 극성에 따라 추출 비율이 상이해질 수 있으므로, 상기 원료에 함유된 피부 개선을 위한 유효성분의 함량을 극대화하기 위해 추출 용매의 특성을 달리할 수 있으며, 용매의 극성에 따라 추출되는 유효성분이 상이할 수 있으므로 최적의 피부 개선 효과가 구현될 수 있도록 상기 에탄올의 농도를 적절히 제어할 수 있다.Since the active ingredient included in the raw material may have a different extraction ratio depending on the polarity of the solvent, the characteristics of the extraction solvent may be varied to maximize the content of the active ingredient for skin improvement contained in the raw material, and the solvent Since the active ingredients extracted may be different depending on the polarity, the concentration of the ethanol may be appropriately controlled so that an optimal skin improvement effect may be realized.
본 발명자들은 상기 농도 범위의 에탄올을 추출 용매로 하였을 때 상기 복합 추출물의 모공 수축 활성을 포함하는 피부 개선 활성이 현저히 개선될 수 있음을 확인하였다.The present inventors have confirmed that the skin improvement activity including the pore contraction activity of the complex extract can be significantly improved when ethanol in the above concentration range is used as an extraction solvent.
상기 에탄올은 농도가 80%(v/v) 초과이면 적정한 수율이 구현되지 않을 수 있고, 농도가 60%(v/v) 미만이면 피부 개선을 위한 유효성분이 충분하게 추출되지 않아 모공 수축 활성이 저하될 수 있다.If the concentration of ethanol is greater than 80% (v/v), an appropriate yield may not be realized, and if the concentration is less than 60% (v/v), active ingredients for skin improvement are not sufficiently extracted, resulting in reduced pore contraction activity. It can be.
상기 화장료 조성물은 항산화 또는 항염증 용도를 더 포함할 수 있다.The cosmetic composition may further include antioxidant or anti-inflammatory applications.
상기 “항산화(anti-oxidant)”는 산화를 억제하는 작용을 의미하는 것으로, 인체는 산화촉 진물질과 산화억제물질이 균형을 이루고 있으나, 여러 가지 요인들로 인하여 이러한 균형 상태를 잃고 산화를 촉진하는 방향으로 기울게 되면, 생체 내에 산화적 스트레스(oxidative stress)가 유발되어 세포손상 및 병리적 질환을 유발할 수 있다.The “anti-oxidant” refers to an action that inhibits oxidation. In the human body, oxidation promoters and oxidation inhibitors are in balance, but due to various factors, this balance is lost and oxidation is promoted. If it is tilted in the direction, oxidative stress is induced in the living body, which can cause cell damage and pathological diseases.
상기 산화적 스트레스의 직접적 원인이 되는 활성 산소종(reactive oxygen species, ROS)은 화학적으로 불안정하고 반응성이 높아 DNA, 단백질, 지질 및 탄수화물과 같은 여러 생체물질과 쉽게 반응할 수 있으며, 생체 내 고분자들을 공격하여 세포와 조직에 비가역적인 손상을 일으키거나 돌연변이, 세포독성 및 암 등을 초래하게 되고, 노화의 직접적인 원인이 되므로, 상기 활성 산소종을 제거하거나 감소시킴으로써 노화를 방지하고 건강을 유지할 수 있다.Reactive oxygen species (ROS), which is a direct cause of the oxidative stress, are chemically unstable and highly reactive, and can easily react with various biomaterials such as DNA, proteins, lipids, and carbohydrates. Aging can be prevented and health can be maintained by removing or reducing the reactive oxygen species, since they cause irreversible damage to cells and tissues or cause mutations, cytotoxicity, cancer, etc., and are a direct cause of aging.
상기 “항염(anti-inflamatory)”은 염증 개선 효과를 의미한다. The “anti-inflamatory” means an effect of improving inflammation.
상기 “염증”은 생체나 조직에 물리적 작용이나 화학적 물질, 세균 감염 등의 어떠한 기질적 변화를 가져오는 침습이 가해질 때 그 손상부위를 수복 재생하려는 기전으로, 일단 자극이 가해지면 국소적으로 히스타민, 세로토닌, 브라디키닌, 프로스타글란딘, HETE(hydroxyeicosatetraenoic acid), 류코트리엔과 같은 혈관 활성 물질이 유리되어 혈관 투과성이 증대되면서 염증이 유발될 수 있다.The "inflammation" is a mechanism for restoring and regenerating the damaged area when an invasion that causes any organic change such as physical action, chemical substance, bacterial infection, etc. is applied to a living body or tissue. Once stimulation is applied, histamine, Inflammation may be induced as vascular active substances such as serotonin, bradykinin, prostaglandin, HETE (hydroxyeicosatetraenoic acid), and leukotrienes are liberated to increase vascular permeability.
또한, 상기 화장료 조성물은 피부 탄력 개선 또는 항노화 용도를 더 포함할 수 있다.In addition, the cosmetic composition may further include skin elasticity improvement or anti-aging purposes.
상기 "피부 탄력"은 피부에 압력을 가했을 때 버티거나 복원되는 힘으로, 엘라스틴으로 구성된 탄력섬유는 콜라겐과 함께 존재하고, 엘라스틴과 콜라겐이 충분히 존재하는 상태에서 피부 탄력이 유지 또는 향상될 수 있으며, 피부 탄력 개선을 통해 모공 수축에 영향을 미칠 수도 있다.The "skin elasticity" is a force that is sustained or restored when pressure is applied to the skin, and elastic fibers composed of elastin exist together with collagen, and skin elasticity can be maintained or improved in a state in which elastin and collagen are sufficiently present, It can also affect pore shrinkage by improving skin elasticity.
상기 “항노화”는 햇빛을 포함하여 여러 가지 요인에 의해서 진피 속의 콜라겐섬유, 탄력섬유 등에 변성이 일어나고, 피부노화에 의해서 피부탄력이 떨어져 피부가 접히게 되면서 주름이 만들어지는 현상을 개선하고, 피부 항상성을 유지 또는 강화시키는 것을 의미한다.The "anti-aging" means that collagen fibers and elastic fibers in the dermis are denatured by various factors, including sunlight, and skin elasticity is reduced due to skin aging, thereby improving the phenomenon of wrinkles being formed as the skin folds. means to maintain or enhance homeostasis.
또한, 상기 화장료 조성물은 피부 온도 감소 용도를 더 포함할 수 있다.In addition, the cosmetic composition may further include a skin temperature reduction application.
상기 “피부 온도 감소”는 피부 표면의 온도를 낮추어 혈관과 모공을 수축시키는 것으로, 본 발명에 따른 복합 추출물은 피부 온도를 효과적으로 저하시키고 피부 수분량을 증가시킴으로써 피부 항상성을 효과적으로 유지시킬 수 있다.The "reduction of skin temperature" is to contract blood vessels and pores by lowering the temperature of the skin surface, and the complex extract according to the present invention can effectively maintain skin homeostasis by effectively lowering skin temperature and increasing skin moisture.
상기 화장료 조성물은 유연화장수, 영양화장수, 수분크림, 영양크림, 마사지크림, 에센스, 앰플, 젤, 아이크림, 클렌징크림, 클렌징폼, 클렌징워터, 팩, 스프레이 및 파우더로 이루어진 군에서 선택된 하나 이상으로 제형화될 수 있다.The cosmetic composition is at least one selected from the group consisting of softening lotion, nutrient lotion, moisture cream, nutrient cream, massage cream, essence, ampoule, gel, eye cream, cleansing cream, cleansing foam, cleansing water, pack, spray, and powder can be formulated.
상기 화장료 조성물은 통상의 방법에 의해 제형화될 수 있다. 상기 화장료 조성물의 제형화에 있어서 International cosmetic ingredient dictionary, 6th ed(The cosmetic, Toiletry and Fragrance Association, Inc., Washington, 1995)에 개시되어 있는 내용을 참조할 수 있다.The cosmetic composition may be formulated by conventional methods. For formulation of the cosmetic composition, reference may be made to information disclosed in International Cosmetic Ingredient Dictionary, 6th ed (The Cosmetic, Toiletry and Fragrance Association, Inc., Washington, 1995).
구체적으로, 상기 화장료 조성물은 일반적인 유화 제형 및 가용화 제형으로 제조할 수 있다. 예컨대, 유연 화장수 또는 영양 화장수 등의 화장수; 훼이셜 로션, 바디로션 등의 유액; 영양 크림, 수분 크림, 아이 크림 등의 크림; 에센스; 화장연고; 스프레이; 젤; 팩; 선 스크린; 메이크업 베이스; 액체 타입, 고체 타입 또는 스프레이 타입 등의 파운데이션; 파우더; 클렌징 크림, 클렌징 로션, 클렌징 오일 등의 메이크업 제거제; 또는 클렌징 폼, 비누, 바디워시 등의 세정제로 제형화될 수 있으나 이에 한정되는 것은 아니다. Specifically, the cosmetic composition may be prepared in a general emulsified formulation and solubilized formulation. For example, cosmetic lotion, such as softening lotion or nourishing lotion; emulsions such as facial lotion and body lotion; creams such as nourishing creams, moisture creams, and eye creams; essence; cosmetic ointment; spray; gel; pack; sunscreen; makeup base; foundations such as liquid type, solid type or spray type; powder; makeup removers such as cleansing creams, cleansing lotions, and cleansing oils; Alternatively, it may be formulated as a cleanser such as a cleansing foam, soap, body wash, etc., but is not limited thereto.
상기 화장료 조성물은 각각의 제형에 있어서 상기 필수성분 외에 제형의 종류 또는 사용 목적 등에 따라 본 발명에 따른 목적을 저해하지 않는 범위 내에서 다른 성분들이 적절히 배합될 수 있다.In addition to the essential components in each formulation, the cosmetic composition may be appropriately mixed with other components within a range that does not impair the purpose of the present invention depending on the type of formulation or purpose of use.
상기 화장료 조성물은 통상적으로 허용 가능한 담체를 포함할 수 있으며, 예컨대 유분, 물, 계면활성제, 보습제, 저급 알코올, 증점제, 킬레이트제, 색소, 방부제, 향료 등을 적절히 배합할 수 있으나, 이에 한정되는 것은 아니다.The cosmetic composition may include a conventionally acceptable carrier, and for example, oil, water, a surfactant, a moisturizer, a lower alcohol, a thickener, a chelating agent, a colorant, a preservative, a flavoring agent, and the like may be appropriately blended, but are not limited thereto. no.
상기 허용 가능한 담체는 제형에 따라 달리할 수 있다. 예컨대, 연고, 페이스트, 크림 또는 젤로 제형화될 때 담체 성분으로서 동물성 유, 식물성 유, 왁스, 파라핀, 전분, 트라칸트, 셀룰로오스 유도체, 폴리에틸렌 글리콜, 실리콘, 벤토나이트, 실리카, 탈크, 산화아연 또는 이들의 추출물이 사용될 수 있다.The acceptable carrier may vary depending on the formulation. For example, animal oil, vegetable oil, wax, paraffin, starch, tracanthate, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc, zinc oxide or any of these as a carrier component when formulated into an ointment, paste, cream or gel extracts may be used.
상기 화장료 조성물은 파우더 또는 스프레이로 제형화될 때, 담체 성분으로서 락토스, 탈크, 실리카, 알루미늄 히드록사이드, 칼슘 실케이트, 폴리아미드 파우더 또는 이들의 추출물이 사용될 수 있고, 스프레이의 경우 클로로플루오로히드로카본, 프로판, 부탄 또는 디메틸 에테르와 같은 추진제를 더 포함할 수 있다.When the cosmetic composition is formulated as a powder or spray, lactose, talc, silica, aluminum hydroxide, calcium silicate, polyamide powder or extracts thereof may be used as a carrier component, and in the case of a spray, chlorofluorohydro It may further contain a propellant such as carbon, propane, butane or dimethyl ether.
상기 화장료 조성물은 용액 또는 유탁액으로 제형화될 때, 담체 성분으로서 용매, 용해화제, 또는 유탁화제가 사용될 수 있고, 예컨대 물, 에탄올, 이소프로판올, 에틸 카보네이트, 에틸 아세테이트, 벤질 벤조에이트, 프로필렌 글리콜, 1,3-브틸글리콜 오일이 사용될 수 있고, 특히, 목화씨 오일, 땅콩 오일, 옥수수 배종 오일, 올리브 오일, 피마자 오일 및 참깨 오일, 글리세롤 지방족 에스테르, 폴리에틸렌 글리콜 또는 소르비탄의 지방산 에스테르가 사용될 수 있다.When the cosmetic composition is formulated as a solution or emulsion, a solvent, solubilizing agent, or emulsifying agent may be used as a carrier component, such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl benzoate, propylene glycol, 1,3-butyl glycol oil may be used, and in particular, cottonseed oil, peanut oil, corn germ oil, olive oil, castor oil and sesame oil, fatty acid esters of glycerol, polyethylene glycol or sorbitan may be used.
상기 화장료 조성물은 현탁액으로 제형화될 때, 담체 성분으로서 물, 에탄올 또는 프로필렌 글리콜과 같은 액상의 희석제, 에톡실화 이소스테아릴 알코올, 폴리옥시에틸렌 소르비톨 에스테르 및 폴리 옥시에틸렌 소르비탄 에스테르와 같은 현탁제, 미소결정성 셀룰로오스, 알루미늄 메타히드록시드, 벤토나이트, 아가 또는 트라칸트 등이 사용될 수 있다.When the cosmetic composition is formulated as a suspension, as a carrier component, a liquid diluent such as water, ethanol or propylene glycol, an ethoxylated isostearyl alcohol, a suspending agent such as polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, Microcrystalline cellulose, aluminum metahydroxide, bentonite, agar or tracanth and the like can be used.
상기 화장료 조성물이 비누로 제형화될 때, 담체 성분으로서 지방산의 알칼리 금속 염, 지방산 헤미에스테르 염, 지방산 단백질 히드롤리제이트, 이세티오네이트, 라놀린 유도체, 지방족 알코올, 식물성 유, 글리세롤, 당 등이 사용될 수 있다.When the cosmetic composition is formulated as a soap, alkali metal salts of fatty acids, fatty acid hemiester salts, fatty acid protein hydrolyzates, isethionates, lanolin derivatives, fatty alcohols, vegetable oils, glycerol, sugars, etc. can be used
상기 화장료 조성물은 최종 제품의 품질이나 기능에 따라 업계에서 통상적으로 사용되는 지방 물질, 유기용매, 용해제, 농축제, 겔화제, 연화제, 항산화제, 현탁화제, 안정화제, 발포제(foaming agent), 방향제, 계면활성제, 물, 이온형 또는 비이온형 유화제, 충전제, 금속이온봉 쇄제, 킬레이트화제, 보존제, 차단제, 습윤화제, 필수 오일, 염료, 안료, 친수성 또는 친유성 활성제, 화장품에 통상적으로 사용되는 임의의 다른 성분과 같은 화장품학 또는 피부과학 분야에서 통상적으로 사용되는 보조제를 추가적으로 함유할 수 있다.The cosmetic composition includes fatty substances, organic solvents, solubilizers, thickeners, gelling agents, softeners, antioxidants, suspending agents, stabilizers, foaming agents, and fragrances commonly used in the industry depending on the quality or function of the final product. , surfactants, water, ionic or nonionic emulsifiers, fillers, sequestering agents, chelating agents, preservatives, blocking agents, wetting agents, essential oils, dyes, pigments, hydrophilic or lipophilic actives commonly used in cosmetics It may additionally contain adjuvants commonly used in cosmetology or dermatology, such as any other ingredient.
다만, 상기 보조제 및 그 혼합 비율은 본 발명에 따른 화장료 조성물의 바람직한 성질에 영향을 미치지 않도록 적절히 선택할 수 있다.However, the adjuvant and its mixing ratio may be appropriately selected so as not to affect desirable properties of the cosmetic composition according to the present invention.
이하 실시예를 통해, 본 발명을 더욱 상술하나 하기 실시예에 의해 본 발명이 제한되지 아니함은 자명하다.Through the following examples, the present invention is further detailed, but it is obvious that the present invention is not limited by the following examples.
제조예 1Preparation Example 1
사과 부산물(사과피 및 사과박), 율피, 감나무잎을 수세한 후 상온에서 완전히 건조시키고 분쇄하여 분쇄물을 각각 500g씩 수득하였다.Apple by-products (apple skin and apple peel), Yulpi, and persimmon leaves were washed with water, completely dried at room temperature, and pulverized to obtain 500 g each of the pulverized products.
각 분쇄물 및 원료에 대해 각각 10배 부피의 증류수를 용매로 하여 80℃의 온도에서 12시간 동안 침적 추출하였다.For each pulverized product and raw material, immersion extraction was performed at 80° C. for 12 hours using 10 times the volume of distilled water as a solvent.
상기 추출물을 300메쉬 및 0.45㎛ 필터로 여과한 후 잔여 원료에 대해 동일한 방법으로 3회 반복 추출하였으며, 80℃-100℃에서 감압 농축하고, 동결 건조하여 천연 추출물의 고형분을 수득하였다.After filtering the extract with a 300 mesh and 0.45 μm filter, the remaining raw material was extracted three times in the same manner, concentrated under reduced pressure at 80° C.-100° C., and freeze-dried to obtain a solid content of the natural extract.
제조예 2Preparation Example 2
제조예 1과 동일한 방법으로 제조하되, 추출 용매로서 70%(v/v) 메탄올을 사용하였다.It was prepared in the same manner as in Preparation Example 1, but 70% (v / v) methanol was used as an extraction solvent.
제조예3Preparation Example 3
제조예 1과 동일한 방법으로 제조하되, 추출 용매로서 70%(v/v) 에탄올을 사용하였다.It was prepared in the same way as in Preparation Example 1, but 70% (v / v) ethanol was used as an extraction solvent.
비교제조예 1Comparative Preparation Example 1
제조예 1과 동일한 방법으로 제조하되, 사과 부산물 대신 사과 과육을 추출 원료로서 사용하였다.It was prepared in the same manner as in Preparation Example 1, but instead of apple by-products, apple flesh was used as an extraction raw material.
비교제조예 2Comparative Preparation Example 2
제조예 2와 동일한 방법으로 제조하되, 사과 부산물 대신 사과 과육을 추출 원료로서 사용하였다.It was prepared in the same manner as in Preparation Example 2, but instead of apple by-products, apple flesh was used as an extraction raw material.
비교제조예 3Comparative Preparation Example 3
제조예 3와 동일한 방법으로 제조하되, 사과 부산물 대신 사과 과육을 추출 원료로서 사용하였다.It was prepared in the same manner as in Preparation Example 3, but instead of apple by-products, apple flesh was used as an extraction raw material.
실시예 및 비교예Examples and Comparative Examples
본 발명의 천연 복합 성분의 안정성 및 기능성을 검증하고자 하기 표 1 및 2와 같이 시료를 혼합하여 실시예 및 비교예를 설정하였다. In order to verify the stability and functionality of the natural composite component of the present invention, examples and comparative examples were set by mixing samples as shown in Tables 1 and 2 below.
(제조예 1)Apple Byproduct Extract
(Production Example 1)
(제조예 1)Yulpi Extract
(Production Example 1)
(제조예 1)Persimmon Leaf Extract
(Production Example 1)
(제조예 2)Apple Byproduct Extract
(Production Example 2)
(제조예 2)Yulpi Extract
(Production Example 2)
(제조예 2)Persimmon Leaf Extract
(Production Example 2)
(제조예 3)Apple Byproduct Extract
(Production Example 3)
(제조예 3)Yulpi Extract
(Production Example 3)
(제조예 3)Persimmon Leaf Extract
(Production Example 3)
(제조예 1)Apple Byproduct Extract
(Production Example 1)
(제조예 1)Yulpi Extract
(Production Example 1)
(제조예 1)Persimmon Leaf Extract
(Production Example 1)
(제조예 3)Apple Byproduct Extract
(Production Example 3)
(제조예 3)Yulpi Extract
(Production Example 3)
(제조예 3)Persimmon Leaf Extract
(Production Example 3)
(비교제조예 1)apple extract
(Comparative Manufacturing Example 1)
(비교제조예 2)apple extract
(Comparative Manufacturing Example 2)
(비교제조예 3)apple extract
(Comparative Manufacturing Example 3)
실험예 1 : 피부 안전성 시험Experimental Example 1: Skin safety test
실시예 및 비교예의 시료에 대한 피부 안전성을 검증하기 위해, Fibroblast, Raw264.7 및 HaCaT cell 대한 WST-1 assay 실험을 수행하였다.In order to verify the skin safety of the samples of Examples and Comparative Examples, WST-1 assay experiments were performed on Fibroblast, Raw264.7 and HaCaT cells.
실시예 및 비교예의 따른 조성물을 농도 별로 처리하여 WST-1 assay로 세포의 생존율을 확인하였다. WST는 살아있는 세포의 양을 측정하는 제품으로써 cell viability를 측정하는데 사용된다. 96 well plate에 각각의 셀을 2 X 104 cells/well로 시딩(seeding)하고, 5% CO2, 37℃ 배양기에서 24시간 배양하였다.The compositions according to Examples and Comparative Examples were treated for each concentration, and cell viability was confirmed by WST-1 assay. WST is a product that measures the amount of living cells and is used to measure cell viability. Each cell was seeded in a 96 well plate at 2
배양 후, 세럼 프리 배지로 교체하여 starvation 시키고 24시간 배양하였다.After culturing, it was replaced with a serum-free medium for starvation and cultured for 24 hours.
실시예 및 비교예 조성물을 각각의 농도로 처리하여 5% CO2, 37℃ 배양기에서 24시간 배양한 후, WST-1 solution을 처리하고 2시간 배양하였다. The compositions of Examples and Comparative Examples were treated at respective concentrations and cultured for 24 hours in a 5% CO 2 , 37°C incubator, and then treated with WST-1 solution and cultured for 2 hours.
배양 후, 흡광도 측정 기기(Multiskan GO, Thermo Fisher Scientific)로 450 nm에서 흡광도를 측정하였다.After incubation, absorbance was measured at 450 nm with an absorbance measuring instrument (Multiskan GO, Thermo Fisher Scientific).
측정 결과, 각 시료의 모든 농도에서 세포 독성은 확인되지 않았다. 상기 결과는 상기 시료가 인체에 무해할 뿐만 아니라 인체 안전성이 우수함을 시사한다.As a result of the measurement, cytotoxicity was not confirmed at all concentrations of each sample. The results suggest that the sample is not only harmless to the human body but also has excellent human safety.
실험예 2 : 모공 축소 활성 평가Experimental Example 2: Pore reduction activity evaluation
실시예 및 비교예의 시료를 제형화한 화장료 조성물의 모공 축소 효과를 평가하였다.The pore shrinking effect of the cosmetic compositions formulated with the samples of Examples and Comparative Examples was evaluated.
상기 각 시료를 동일한 조성으로 제형화하였으며, 피험자를 나누어 각각 적용한 후 모공 축소 효과를 검증하였다.Each of the above samples was formulated with the same composition, and the pore reduction effect was verified after each application was applied to the subjects separately.
모공 축소 효과를 검증하기 위해 모공 부위 치밀도, 모공 면적, 모공 부피, 모공 부위 탄력 변화율을 측정하였다(표 3). To verify the pore shrinking effect, pore density, pore area, pore volume, and pore elasticity change rates were measured (Table 3).
모공 부위 치밀도는 DUB Skinscanner를 이용하여 측정하였으며, 모공 면적 및 부피는 Antera 3D CS, 모공 부위 탄력은 Ballistometer BLS780를 이용하여 측정하였다.Pore density was measured using DUB Skinscanner, pore area and volume were measured using Antera 3D CS, and pore elasticity was measured using Ballistometer BLS780.
변화율은 사용 전 측정 결과와 사용 4주 후의 측정 결과의 변화율을 산출하였다. For the change rate, the change rate of the measurement result before use and the measurement result after 4 weeks of use was calculated.
변화율(%)Change rate (%)
변화율(%)Change rate (%)
변화율(%)Change rate (%)
변화율(%)Change rate (%)
표 3을 참조하면, 실시예의 시료는 비교예 대비 모공 축소 활성이 현저히 우수하였다.Referring to Table 3, the samples of Examples were significantly superior in pore shrinking activity compared to Comparative Examples.
구체적으로, 실시예 1 내지 3의 복합 시료에서 사과 부산물 및 율피 추출물의 중량비가 5:3.5 인 실시예 3의 모공 축소 활성이 상대적으로 우수한 것으로 평가되었다.Specifically, in the composite samples of Examples 1 to 3, the pore shrinking activity of Example 3 in which the weight ratio of the apple by-product and Yulpi extract was 5:3.5 was evaluated to be relatively excellent.
실시예 4 내지 6의 경우 감나무잎 추출물 추가에 따라 모공 축소 활성이 더욱 개선되었으며, 사과 부산물 추출물, 율피 추출물, 감나무 잎 추출물의 중량비가 5:3.5:1.5인 실시예 6의 모공 축소 활성이 더욱 우수한 것으로 나타났다.In the case of Examples 4 to 6, the pore shrinking activity was further improved according to the addition of persimmon leaf extract, and the pore shrinking activity of Example 6 in which the weight ratio of apple by-product extract, yulpi extract, and persimmon leaf extract was 5: 3.5: 1.5 was more excellent appeared to be
실시예 7 내지 10의 경우 추출 용매를 메탄올 또는 에탄올로 달리한 것으로, 에탄올을 추출 용매로 사용한 실시예 9 및 10의 모공 축소 활성은 유의적으로 높은 수준으로 평가되었다(도 1 및 도 2).In the case of Examples 7 to 10, the extraction solvent was changed to methanol or ethanol, and the pore shrinking activity of Examples 9 and 10 using ethanol as the extraction solvent was evaluated at a significantly high level (FIGS. 1 and 2).
반면, 비교예 1내지 6은 단일 추출물의 모공 축소 활성을 평가한 것으로, 실시예 대비 낮은 수준의 모공 축소 활성이 확인되었다.On the other hand, Comparative Examples 1 to 6 evaluated the pore-reducing activity of a single extract, and a lower level of pore-reducing activity was confirmed compared to the examples.
또한, 비교예 7 및 8은 사과 부산물 추출물 및 율피 추출물을 동시에 포함하지 않는 복합 추출물 시료로서, 사과 부산물 추출물 및 율피 추출물 중 일부를 포함하지 않는 경우에는 조합에 따른 상승 효과가 거의 나타나지 않았다.In addition, Comparative Examples 7 and 8 are composite extract samples that do not contain the apple by-product extract and the yulpi extract at the same time.
비교예 9 내지 12의 경우 사과 부산물 추출물이 아닌 사과 과육 추출물을 조합한 것으로, 조합에 따른 모공 축소 활성은 상대적으로 낮은 수준으로 평가되었다.In Comparative Examples 9 to 12, the apple pulp extract was combined instead of the apple by-product extract, and the pore shrinking activity according to the combination was evaluated at a relatively low level.
상기 결과는 사과 부산물 추출물 및 율피 추출물이 동시에 작용하여 시너지 활성이 구현될 수 있으며, 사과 부산물 추출물 및 율피 추출물의 조성비 및 추출 용매를 최적화함으로써 우수한 모공 축소 활성이 구현될 수 있음을 시사한다.The above results suggest that synergistic activity can be realized by the simultaneous action of apple by-product extract and yulpi extract, and excellent pore-reducing activity can be realized by optimizing the composition ratio and extraction solvent of apple by-product extract and yulpi extract.
실험예 3 : 자유라디칼 소거 활성 평가Experimental Example 3: Evaluation of free radical scavenging activity
실시예 및 비교예의 추출물을 정제수에 현탁하여 자유라디칼 소거 활성(free radical scavenging acticity)을 평가하였다.Extracts of Examples and Comparative Examples were suspended in purified water to evaluate free radical scavenging acticity.
DPPH 측정법은 억제제(inhibitor)가 안정한 라디칼 DPPH(2,2-Diphenyl-1-picrylhydrazyl radical)를 소거하여 탈색되는 정도를 540nm에서 흡광도를 측정하는 방법이다.The DPPH measurement method is a method of measuring absorbance at 540 nm to determine the degree of decolorization by scavenging the stable radical DPPH (2,2-Diphenyl-1-picrylhydrazyl radical) by an inhibitor.
양성대조군으로 L-Ascorbic acid를 이용하였고, 실험의 정확도를 위하여 동일한 실험을 3회 반복하였으며, 결과(시료 농도 1mg/mL)는 하기 표 4와 같다.L-Ascorbic acid was used as a positive control group, and the same experiment was repeated three times for the accuracy of the experiment, and the results (
표 4를 참조하면, 실시예의 시료는 비교예 대비 항산화 효과가 현저히 우수하였다.Referring to Table 4, the samples of Examples were significantly superior in antioxidant effect compared to Comparative Examples.
구체적으로, 실시예 1 내지 3의 복합 시료의 경우 사과 부산물 및 율피 추출물의 중량비가 5:3.5 인 실시예 3의 항산화 활성이 상대적으로 우수한 것으로 평가되었다.Specifically, in the case of the composite samples of Examples 1 to 3, the antioxidant activity of Example 3 in which the weight ratio of the apple by-product and the Yulpi extract was 5:3.5 was evaluated to be relatively excellent.
또한, 실시예 4 내지 6의 경우 감나무잎 추출물 추가에 따라 항산화 활성이 더욱 개선되었으며, 사과 부산물 추출물, 율피 추출물, 감나무잎 추출물의 중량비가 5:3.5:1.5 인 실시예 6의 항산화 활성이 더욱 우수한 것으로 평가되었다.In addition, in the case of Examples 4 to 6, the antioxidant activity was further improved according to the addition of persimmon leaf extract, and the antioxidant activity of Example 6 in which the weight ratio of apple by-product extract, yulpi extract, and persimmon leaf extract was 5: 3.5: 1.5 was more excellent was evaluated as
실시예 7 내지 10의 경우 추출 용매를 메탄올 또는 에탄올로 달리하였는데, 에탄올을 추출 용매로 사용한 실시예 9 및 10의 항산화 활성은 유의적으로 높은 수준으로 평가되었다(도 2).In the case of Examples 7 to 10, the extraction solvent was changed to methanol or ethanol, and the antioxidant activity of Examples 9 and 10 using ethanol as the extraction solvent was evaluated at a significantly high level (FIG. 2).
반면, 비교예 1내지 6은 단일 추출물의 항산화 활성을 평가한 것으로, 항산화 활성은 실시예 대비 상대적으로 낮은 수준으로 평가되었다.On the other hand, Comparative Examples 1 to 6 were to evaluate the antioxidant activity of a single extract, the antioxidant activity was evaluated at a relatively low level compared to the examples.
또한, 비교예 7 및 8은 사과 부산물 추출물 및 율피 추출물을 동시에 포함하지 않는 복합 추출물 시료에 해당하며, 사과 부산물 추출물 및 율피 추출물 중 일부를 포함하지 않는 경우에는 조합에 따른 상승 효과가 거의 나타나지 않았다.In addition, Comparative Examples 7 and 8 correspond to composite extract samples that do not contain apple by-product extract and yulpi extract at the same time.
비교예 9 내지 12의 경우 사과 부산물 추출물이 아닌 사과 과육 추출물을 투입한 것으로, 조합에 따른 시너지 활성이 상대적으로 낮은 수준으로 평가되었다.In the case of Comparative Examples 9 to 12, the apple pulp extract was added instead of the apple by-product extract, and the synergistic activity according to the combination was evaluated at a relatively low level.
상기 결과는 사과 부산물 추출물 및 율피 추출물이 동시에 작용함으로써 시너지 활성이 구현될 수 있으며, 사과 부산물 추출물 및 율피 추출물의 혼합 비율 및 추출 용매를 최적화함으로써 더욱 우수한 항산화 활성이 구현될 수 있음을 시사한다.The above results suggest that synergistic activity can be realized by the simultaneous action of apple by-product extract and yulpi extract, and better antioxidant activity can be realized by optimizing the mixing ratio and extraction solvent of apple by-product extract and yulpi extract.
실험예 4 : 항염 활성 평가Experimental Example 4: Evaluation of anti-inflammatory activity
RAW264.7 세포를 카운팅한 뒤 2.5 x 105 cells/well이 되도록 희석 후, 48 well plate에 2.5 x 105 cells/well 세포를 시딩(seeding)하고 5% CO2, 37℃ 배양기에서 24시간 동안 배양하였다. After counting RAW264.7 cells and diluting to 2.5 x 10 5 cells/well, seeding the cells at 2.5 x 10 5 cells/well in a 48 well plate and incubating at 5% CO 2 and 37°C for 24 hours. cultured.
배양 후 세럼 프리 배지로 교체 후 starvation시키고, 실시예 및 비교예의 시료를 농도별로 각각 희석하여 처리하였다. After culturing, the medium was replaced with a serum-free medium, followed by starvation, and the samples of Examples and Comparative Examples were diluted and treated by concentration, respectively.
양성 대조군으로 사용하는 DEX(Dexamethasone)는 20 μg/mL로 처리 후 5% CO2, 37℃ 배양기에서 1시간 배양하고 LPS(Lipopolysaccharide)가 1 μg/mL이 되도록 처리 후 5% CO2, 37℃ 배양기에서 24시간 배양하였다.DEX (Dexamethasone) used as a positive control was treated with 20 μg/mL, then incubated for 1 hour in an incubator at 5% CO 2 , 37°C, and treated to 1 μg/mL of LPS (Lipopolysaccharide) at 5% CO 2 , 37°C. Incubated for 24 hours in an incubator.
합성된 NO를 포함하는 배지 100 μL를 96 well plate로 옮기고 500 μM NaNO2를 기준으로 사용하여 각각의 농도별로 96 well plate에 처리 후 20분 동안 실온에서 반응시켰다. 100 μL of the medium containing the synthesized NO was transferred to a 96 well plate, and 500 μM NaNO 2 was used as a standard for each concentration in the 96 well plate, followed by reaction at room temperature for 20 minutes.
흡광도 측정을 위해 multiskan GO 프로그램을 실행 후 흡광도를 540nm로 설정하고, 플레이트에 측정 영역을 선택하고 흡광도를 측정하였다. After running the multiskan GO program for absorbance measurement, the absorbance was set to 540 nm, a measurement region was selected on the plate, and the absorbance was measured.
각각의 합성된 Nitric Oxide의 값을 표준 곡선을 이용하여 계산하고, 그 값의 평균으로 결과 값을 도출하여, NO의 생성량 측정을 통한 항염 효과를 확인하였다The value of each synthesized Nitric Oxide was calculated using a standard curve, and the resultant value was derived from the average of the values, and the anti-inflammatory effect was confirmed by measuring the amount of NO produced.
실시예 및 비교예 시료(300 μg/mL) 처리에 따른 NO의 생성량을 측정하였다(표 5). The production amount of NO according to the treatment of Examples and Comparative Examples (300 μg/mL) was measured (Table 5).
표 5를 참조하면, 실시예 1 내지 10의 시료는 비교예 1 내지 12 대비 NO(Nitric oxide) 생성 억제 활성이 우수하였다.Referring to Table 5, the samples of Examples 1 to 10 were superior in nitric oxide (NO) generation inhibitory activity compared to Comparative Examples 1 to 12.
구체적으로, 실시예 1 내지 3의 복합 시료의 경우 사과 부산물 및 율피 추출물의 중량비가 5:3.5 인 실시예 3의 항염 활성이 상대적으로 우수한 것으로 평가되었다.Specifically, in the case of the composite samples of Examples 1 to 3, the anti-inflammatory activity of Example 3 in which the weight ratio of apple by-products and Yulpi extract was 5:3.5 was evaluated to be relatively excellent.
또한, 실시예 4 내지 6의 경우 감나무잎 추출물 추가에 따라 항염 활성이 더욱 개선되었으며, 사과 부산물 추출물, 율피 추출물, 감나무 잎 추출물의 중량비가 5:3.5:1.5 인 실시예 6의 항염 활성이 더욱 우수한 것으로 평가되었다.In addition, in the case of Examples 4 to 6, the anti-inflammatory activity was further improved by adding persimmon leaf extract, and the anti-inflammatory activity of Example 6 in which the weight ratio of apple by-product extract, yulpi extract, and persimmon leaf extract was 5: 3.5: 1.5 was more excellent was evaluated as
실시예 7 내지 10의 경우 추출 용매를 메탄올 또는 에탄올로 달리하였는데, 에탄올을 추출 용매로 사용한 실시예 9 및 10의 항염 활성은 유의적으로 높은 수준으로 평가되었다(도 3).In the case of Examples 7 to 10, the extraction solvent was changed to methanol or ethanol, and the anti-inflammatory activity of Examples 9 and 10 using ethanol as the extraction solvent was evaluated at a significantly high level (FIG. 3).
반면, 비교예 1내지 6은 단일 추출물의 항염 활성은 실시예 대비 상대적으로 낮은 수준으로 나타났다.On the other hand, in Comparative Examples 1 to 6, the anti-inflammatory activity of a single extract was relatively low compared to the examples.
또한, 비교예 7 및 8은 사과 부산물 추출물 및 율피 추출물을 동시에 포함하지 않는 복합 추출물 시료로서, 사과 부산물 추출물 및 율피 추출물 중 일부를 포함하지 않는 경우에 조합에 따른 상승 효과가 거의 나타나지 않았다.In addition, Comparative Examples 7 and 8 are composite extract samples that do not contain the apple by-product extract and the yulpi extract at the same time.
사과 과육 추출물을 조합한 비교예 9 내지 12의 경우 사과 부산물 추출물 대비 조합에 따른 시너지 활성이 상대적으로 낮은 수준으로 평가되었다.In the case of Comparative Examples 9 to 12 in which the apple pulp extract was combined, the synergistic activity according to the combination was evaluated at a relatively low level compared to the apple by-product extract.
상기 결과는 사과 부산물 추출물 및 율피 추출물이 동시에 작용함으로써 시너지 활성이 구현될 수 있으며, 각 구성의 조합뿐만 아니라, 추출 용매, 혼합 비율을 최적화함으로써 항염 활성을 더욱 증진시킬 수 있음을 시사한다.The above results suggest that synergistic activity can be realized by the simultaneous action of the apple by-product extract and the yulpi extract, and that the anti-inflammatory activity can be further enhanced by optimizing the extraction solvent and mixing ratio as well as the combination of each component.
실험예 5 : 엘라스타제 억제 활성 평가Experimental Example 5: Evaluation of elastase inhibitory activity
엘라스타제(elastase)의 저해 활성을 통해 실시예 및 비교예의 피부 탄력 개선 효과를 평가하였다.The skin elasticity improvement effect of Examples and Comparative Examples was evaluated through the inhibitory activity of elastase.
실시예 및 비교예의 시료의 엘라스타제 저해 활성을 하기와 같이 측정하였다.The elastase inhibitory activity of the samples of Examples and Comparative Examples was measured as follows.
Fibroblast cell을 DMEM 배지에서 배양한 후, 배양한 세포를 0.1% triton X-100/0.2M Tris액(pH8.0)에 세포를 균질화시켰다.After culturing the fibroblast cells in DMEM medium, the cultured cells were homogenized in 0.1% triton X-100/0.2M Tris solution (pH 8.0).
균질화 시킨 용액을 4℃에서 13,000 rpm 으로 20분간 원심 분리한 후, 상층액을 취하여 섬유아세포 엘라스타제를 포함하는 효소액으로 사용하였다.The homogenized solution was centrifuged at 4° C. at 13,000 rpm for 20 minutes, and the supernatant was taken and used as an enzyme solution containing fibroblast elastase.
상층액을 단백질 정량하여 well당 100μg의 단백질을 함유하는 양을 96well에 넣고 0.2M tris-HCL 완충액(pH8.0)을 넣어 88μL가 되도록 하였다.Protein was quantified in the supernatant, and an amount containing 100 μg of protein per well was put into 96 wells, and 0.2M tris-HCL buffer (pH 8.0) was added to make 88 μL.
실시예와 비교예를 농도별로 10μL씩 96well에 넣고 STANA(N-succinyl-tri-alanyl-p-nitroanilide)액을 2μL씩 각 well 당 넣고 37℃에서 배양하고, 90분 후 405nm에서 측정하였다.Examples and Comparative Examples were put into 96 wells by 10 μL for each concentration, and 2 μL of STANA (N-succinyl-tri-alanyl-p-nitroanilide) solution was added to each well, incubated at 37 ° C, and measured at 405 nm after 90 minutes.
1mg/mL 농도의 시료를 첨가하지 않은 흡광도 대비 시료를 첨가한 흡광도의 차의 비율로 엘라스타제 저해 활성의 비율(%)를 측정하고 표 6에 나타내었다. The ratio (%) of the elastase inhibitory activity was measured as the ratio of the difference between the absorbance with the sample added and the absorbance without the sample having a concentration of 1 mg/mL and is shown in Table 6.
엘라스타제(Elastase)는 진피 내 피부 탄력을 유지시키는 데 중요한 기질인 엘라스틴을 분해하는 효소이다. 또한 엘라스타제는 다른 중요한 기질단백질인 콜라겐(collagen)을 분해할 수 있는 비특이적 가수분해 효소이다.Elastase is an enzyme that decomposes elastin, an important substrate for maintaining skin elasticity in the dermis. In addition, elastase is a non-specific hydrolytic enzyme capable of degrading another important matrix protein, collagen.
따라서 높은 엘라스타제 활성 억제율은 피부 탄력을 유지하는데 중요한 엘라스틴과 콜라겐이 오래 유지됨을 의미하며, 이는 피부 탄력 개선 효과가 우수하다는 것을 시사한다.Therefore, a high elastase activity inhibition rate means that elastin and collagen, which are important for maintaining skin elasticity, are maintained for a long time, which suggests that the effect of improving skin elasticity is excellent.
표 6을 참조하면, 사과 부산물 및 율피 추출물의 중량비가 5:3.5 인 실시예 3이 실시예 1 및 2 대비 피부 탄력 개선 활성이 상대적으로 우수한 것으로 평가되었다.Referring to Table 6, Example 3 in which the weight ratio of apple by-products and yulpi extract was 5: 3.5 was evaluated as relatively excellent in skin elasticity improvement activity compared to Examples 1 and 2.
또한, 실시예 4 내지 6의 경우 감나무잎 추출물 추가에 따라 피부 탄력 개선 활성이 더욱 개선되었으며, 사과 부산물 추출물, 율피 추출물, 감나무 잎 추출물의 중량비가 5:3.5:1.5 인 실시예 6의 피부 탄력 개선 활성이 더욱 우수한 것으로 평가되었으며, 에탄올을 추출 용매로 사용한 실시예 9 및 10의 피부 탄력 개선 활성은 유의적으로 높은 수준으로 평가되었다(도 4).In addition, in Examples 4 to 6, the skin elasticity improvement activity was further improved according to the addition of persimmon leaf extract, and the skin elasticity improvement of Example 6 in which the weight ratio of apple by-product extract, yulpi extract, and persimmon leaf extract was 5:3.5:1.5 The activity was evaluated to be more excellent, and the skin elasticity improvement activity of Examples 9 and 10 using ethanol as an extraction solvent was evaluated at a significantly high level (FIG. 4).
반면, 단일 추출물의 피부 탄력 개선 활성을 평가한 비교예 1내지 6의 피부 탄력 개선 활성은 실시예 대비 상대적으로 낮은 수준으로 나타났다.On the other hand, the skin elasticity improvement activity of Comparative Examples 1 to 6, which evaluated the skin elasticity improvement activity of a single extract, was found to be at a relatively low level compared to the examples.
또한, 사과 부산물 추출물 및 율피 추출물을 동시에 포함하지 않는 비교예 7 및 8은 조합에 따른 상승 효과가 거의 나타나지 않았으며, 사과 과육 추출물을 조합한 비교예 9 내지 12의 경우 사과 부산물 추출물 대비 조합에 따른 시너지 활성이 상대적으로 낮은 수준으로 평가되었다.In addition, Comparative Examples 7 and 8, which did not contain the apple by-product extract and the yulpi extract at the same time, showed little synergistic effect according to the combination, and in the case of Comparative Examples 9 to 12 in which the apple pulp extract was combined, compared to the apple by-product extract, according to the combination Synergistic activity was evaluated at a relatively low level.
상기 결과는 사과 부산물 추출물 및 율피 추출물이 동시에 작용함으로써 시너지 활성이 구현될 수 있으며, 각 구성의 조합뿐만 아니라, 추출 용매, 혼합 비율을 최적화함으로써 피부 탄력 개선 활성을 더욱 증진시킬 수 있음을 시사한다.The above results suggest that synergistic activity can be implemented by the simultaneous action of the apple by-product extract and the yulpi extract, and that the skin elasticity improvement activity can be further enhanced by optimizing the extraction solvent and mixing ratio as well as the combination of each component.
실험예 6 : 항노화 활성 평가Experimental Example 6: Evaluation of anti-aging activity
HaCaT cell을 10% FBS(fetal bovine serum)와 1X Penicillin/streptomycin(P/S)이 함유된 DMEM 배지에 배양하고 세포를 카운팅한 뒤 6 cm2 plate에 2 x 105 cells/well이 되도록 희석하여 시딩(seeding)하고 5% CO2, 37℃ 배양기에서 24시간 배양하였다.HaCaT cells were cultured in DMEM medium containing 10% FBS (fetal bovine serum) and 1X Penicillin/streptomycin (P/S), and after counting the cells, diluted to 2 x 10 5 cells/well in a 6 cm 2 plate. After seeding, 5% CO 2 , and cultured for 24 hours in an incubator at 37°C.
또 다른 세포인 Fibroblast cell을 10% FBS 와 1X Penicillin/streptomycin(P/S)이 함유된 FBM 배지에 배양하고 세포를 카운팅 한 뒤 24 well plate에 3 x 104 cells/well이 되도록 희석하여 시딩하고 5% CO2, 37℃ 배양기에서 24시간 배양하였다.Fibroblast cells, another cell, were cultured in FBM medium containing 10% FBS and 1X Penicillin/streptomycin (P/S), and after counting the cells, diluted to 3 x 10 4 cells/well in a 24 well plate and seeded 5% CO 2 , and cultured for 24 hours in an incubator at 37°C.
배양한 HaCaT 세포의 상등액을 제거하고, PBS 워싱한 후 PBS를 1mL 넣고 UV를 15 mJ/cm2조사 하였다.The supernatant of the cultured HaCaT cells was removed, washed with PBS, and 1mL of PBS was added and UV was irradiated at 15 mJ/cm 2 .
PBS를 제거하고, starvation 단계를 위해 1% FBS를 포함하는 DMEM 배양액을 교체 후 5% CO2, 37℃ 배양기에서 24시간 배양하였다.After removing the PBS and replacing the DMEM culture medium containing 1% FBS for the starvation step, the cells were cultured for 24 hours in a 5% CO 2 , 37°C incubator.
UV조사를 한 HaCaT 세포의 상등액과 조사하지 않은 HaCaT 세포의 상등액을 각 50mL 튜브에 옮기고 독성이 없는 농도 범위 기준으로 설정 후, HaCaT 세포의 상등액을 이용하여 희석하였다.The supernatant of UV-irradiated HaCaT cells and the supernatant of unirradiated HaCaT cells were transferred to each 50 mL tube, and after setting the non-toxic concentration range as a standard, the supernatant of HaCaT cells was diluted.
배양한 세포 Fibroblast의 상등액을 제거하였다. HaCaT 상등액을 이용하여 만든 시료들을 배양한 세포 Fibroblast에 농도별로 처리 후 5% CO2, 37℃ 배양기에서 24시간 배양하였다. The supernatant of the cultured cell fibroblast was removed. Samples made using the HaCaT supernatant were treated with the cultured cell Fibroblast at each concentration and then cultured for 24 hours in a 5% CO 2 , 37°C incubator.
배양한 세포 Fibroblast의 상등액을 96 well plate에 150 μL씩 넣었다. Human Total MMP-1 ELISA kit(DY901)를 활용하여 Fibroblast 상등액 내에 존재하는 MMP-1의 양을 정량하였다.150 μL of the supernatant of the cultured cell fibroblast was added to a 96 well plate. The amount of MMP-1 present in the fibroblast supernatant was quantified using the Human Total MMP-1 ELISA kit (DY901).
실시예와 비교예의 시료를 농도별로 처리하여 콜라겐 분해 효소인 MMP-1 발현량이 감소하는지 여부를 확인하였고, 이를 표 7에 나타내었다.Samples of Examples and Comparative Examples were treated for each concentration to confirm whether or not the amount of expression of MMP-1, a collagen degrading enzyme, was reduced, which is shown in Table 7.
시료는 0.6 mg/mL 농도에서 MMP-1 저해활성을 측정하였다.The sample was measured for MMP-1 inhibitory activity at a concentration of 0.6 mg/mL.
표 7을 참조하면, 실시예 1 내지 10의 시료는 비교예 1 내지 12 대비 MMP-1 억제 활성이 우수하였다.Referring to Table 7, the samples of Examples 1 to 10 were superior in MMP-1 inhibitory activity compared to Comparative Examples 1 to 12.
구체적으로, 사과 부산물 및 율피 추출물의 중량비가 5:3.5 인 실시예 3이 실시예 1 및 2 대비 항노화 활성이 상대적으로 우수한 것으로 평가되었으며, 실시예 4 내지 6의 경우 감나무잎 추출물 조합에 따라 항노화 활성이 더욱 개선되었다.Specifically, Example 3, in which the weight ratio of apple by-products and yulpi extract was 5:3.5, was evaluated to have relatively excellent anti-aging activity compared to Examples 1 and 2, and in the case of Examples 4 to 6, anti-aging activity was determined according to the combination of persimmon leaf extract. The aging activity was further improved.
사과 부산물 추출물, 율피 추출물, 감나무 잎 추출물의 중량비가 5:3.5:1.5 인 실시예 6의 항노화 활성이 더 높은 것으로 나타났으며, 에탄올을 추출 용매로 사용한 실시예 9 및 10의 피부 탄력 개선 활성은 유의적으로 높은 수준으로 평가되었다(도 5).The anti-aging activity of Example 6 in which the weight ratio of apple by-product extract, Yulpi extract, and persimmon leaf extract was 5: 3.5: 1.5 was higher, and skin elasticity improvement activity of Examples 9 and 10 using ethanol as an extraction solvent was evaluated at a significantly high level (FIG. 5).
반면, 단일 추출물로 이루어진 비교예 1내지 6의 항노화 활성은 실시예 대비 상대적으로 낮은 수준으로 나타났으며, 사과 부산물 추출물 및 율피 추출물을 동시에 포함하지 않는 비교예 7 및 8은 조합에 따른 상승 효과가 거의 나타나지 않았다.On the other hand, the anti-aging activity of Comparative Examples 1 to 6 consisting of a single extract was found to be at a relatively low level compared to the examples, and Comparative Examples 7 and 8, which did not contain the apple by-product extract and the yulpi extract at the same time, had a synergistic effect according to the combination hardly appeared.
또한, 사과 과육 추출물을 조합한 비교예 9 내지 12의 경우 사과 부산물 추출물 대비 조합에 따른 시너지 활성이 상대적으로 낮은 수준으로 평가되었다.In addition, in the case of Comparative Examples 9 to 12 in which the apple pulp extract was combined, the synergistic activity according to the combination compared to the apple by-product extract was evaluated at a relatively low level.
상기 결과는 사과 부산물 추출물 및 율피 추출물이 동시에 작용함으로써 시너지 활성이 구현될 수 있으며, 각 구성의 조합뿐만 아니라, 추출 용매, 혼합 비율을 최적화함으로써 항노화 활성을 더욱 개선될 수 있음을 시사한다.The above results suggest that synergistic activity can be realized by the simultaneous action of the apple by-product extract and the yulpi extract, and that the anti-aging activity can be further improved by optimizing the extraction solvent and mixing ratio as well as the combination of each component.
실험예 7 : 피부 진정 효과 평가(피부 온도 감소율)Experimental Example 7: Skin soothing effect evaluation (skin temperature reduction rate)
실시예 및 비교예의 시료를 제형화한 화장료 조성물의 피부 온도 감소 효과를 분석하였다.The skin temperature reduction effect of the cosmetic compositions formulated with the samples of Examples and Comparative Examples was analyzed.
상기 각 시료를 동일한 조성으로 제형화한 후 피부온도에 미치는 영향을 분석하기 위해, 제형화한 화장료를 안면의 볼 부위에 적용한 후, 직사광선이 비치는 환경(외부온도 34℃)에서 30분 동안 노출시키고, 볼 부위의 피부 온도 변화를 측정하여 평균값을 산출하였다(표 8).After formulating each sample with the same composition, in order to analyze the effect on skin temperature, the formulated cosmetics were applied to the cheeks of the face, and then exposed for 30 minutes in an environment exposed to direct sunlight (outside temperature 34 ° C), , The average value was calculated by measuring the change in skin temperature in the cheek area (Table 8).
피부 온도 변화량은 시험 전 안면의 온도를 측정한 값과, 직사광선이 비치는 외부 환경에 노출시킨 후 안면의 온도를 측정한 값과의 차이를 산출하였다.The change in skin temperature was calculated as the difference between the measured value of the facial temperature before the test and the measured value of the facial temperature after exposure to the external environment with direct sunlight.
표 8을 참조하면, 실시예의 시료를 포함하는 화장료를 적용한 사용자의 피부 온도는 비교 대비 낮은 수준으로 평가되었으며, 특히, 혼합 비율 및 추출 용매를 최적화함에 따라 피부 온도 감소 효과는 더욱 우수한 것으로 평가되었다.Referring to Table 8, the skin temperature of the user who applied the cosmetic composition containing the example sample was evaluated at a lower level compared to the comparison, and in particular, the skin temperature reduction effect was evaluated as more excellent as the mixing ratio and extraction solvent were optimized.
상기 결과는 사과 부산물 추출물 및 율피 추출물이 동시에 작용함으로써 시너지 활성이 구현될 수 있으며, 각 구성의 조합뿐만 아니라, 추출 용매, 혼합 비율을 최적화함으로써 피부 온도 개선 효과를 극대화할 수 있음을 시사한다.The above results suggest that synergistic activity can be realized by the simultaneous action of the apple by-product extract and the yulpi extract, and that the skin temperature improvement effect can be maximized by optimizing the extraction solvent and mixing ratio as well as the combination of each component.
전술한 본 발명의 설명은 예시를 위한 것이며, 본 발명이 속하는 기술분야의 통상의 지식을 가진 자는 본 발명의 기술적 사상이나 필수적인 특징을 변경하지 않고서 다른 구체적인 형태로 쉽게 변형이 가능하다는 것을 이해할 수 있을 것이다. 그러므로 이상에서 기술한 실시예들은 모든 면에서 예시적인 것이며 한정적이 아닌 것으로 이해해야만 한다. 예를 들어, 단일형으로 설명되어 있는 각 구성 요소는 분산되어 실시될 수도 있으며, 마찬가지로 분산된 것으로 설명되어 있는 구성 요소들도 결합된 형태로 실시될 수 있다.The above description of the present invention is for illustrative purposes, and those skilled in the art can understand that it can be easily modified into other specific forms without changing the technical spirit or essential features of the present invention. will be. Therefore, the embodiments described above should be understood as illustrative in all respects and not limiting. For example, each component described as a single type may be implemented in a distributed manner, and similarly, components described as distributed may be implemented in a combined form.
본 발명의 범위는 후술하는 특허청구범위에 의하여 나타내어지며, 특허청구범위의 의미 및 범위 그리고 그 균등 개념으로부터 도출되는 모든 변경 또는 변형된 형태가 본 발명의 범위에 포함되는 것으로 해석되어야 한다.The scope of the present invention is indicated by the following claims, and all changes or modifications derived from the meaning and scope of the claims and equivalent concepts should be interpreted as being included in the scope of the present invention.
Claims (8)
상기 사과 부산물 추출물 50 중량부 및 상기 율피 추출물 30 내지 40 중량부를 포함하는, 화장료 조성물.According to claim 1,
A cosmetic composition comprising 50 parts by weight of the apple by-product extract and 30 to 40 parts by weight of the yulpi extract.
감나무잎 추출물;을 더 포함하는, 화장료 조성물.According to claim 1,
A cosmetic composition further comprising a; persimmon leaf extract.
상기 사과 부산물 추출물 50 중량부, 상기 율피 추출물 30 내지 40 중량부, 및 상기 감나무잎 추출물 10 내지 20 중량부를 포함하는, 화장료 조성물.According to claim 3,
A cosmetic composition comprising 50 parts by weight of the apple by-product extract, 30 to 40 parts by weight of the yulpi extract, and 10 to 20 parts by weight of the persimmon leaf extract.
상기 추출물은 60 내지 80%(v/v) 농도의 에탄올을 추출 용매로 하여 수득한, 화장료 조성물.According to claim 3,
The extract is obtained by using ethanol at a concentration of 60 to 80% (v / v) as an extraction solvent, a cosmetic composition.
항산화 또는 항염증 용도를 더 포함하는, 화장료 조성물.According to any one of claims 1 to 5,
A cosmetic composition further comprising antioxidant or anti-inflammatory applications.
피부 탄력 개선 용도를 더 포함하는, 화장료 조성물.According to any one of claims 1 to 5,
A cosmetic composition further comprising use for improving skin elasticity.
피부 온도 감소 용도를 더 포함하는, 화장료 조성물.
According to any one of claims 1 to 5,
A cosmetic composition further comprising a skin temperature reduction application.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020230038542A KR102525091B1 (en) | 2023-03-24 | 2023-03-24 | A cosmetic compositon for pore-minimizing comprising natural complex extract as an active ingredient |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020230038542A KR102525091B1 (en) | 2023-03-24 | 2023-03-24 | A cosmetic compositon for pore-minimizing comprising natural complex extract as an active ingredient |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR102525091B1 true KR102525091B1 (en) | 2023-04-24 |
Family
ID=86141585
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020230038542A Active KR102525091B1 (en) | 2023-03-24 | 2023-03-24 | A cosmetic compositon for pore-minimizing comprising natural complex extract as an active ingredient |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR102525091B1 (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100955389B1 (en) * | 2009-06-29 | 2010-04-29 | (주)바이오에프디엔씨 | Cosmetic composition for pore-minimizing and inhibition of sebum secretion containing natural materials |
| KR20200040607A (en) * | 2018-10-10 | 2020-04-20 | 경북대학교 산학협력단 | Composition for anti-oxidation, anti-inflammation, anti-diabetes, pore shrink, or anti-wrinkle comprising extract of Summer prince apple |
| KR102110081B1 (en) * | 2019-07-29 | 2020-05-22 | (주)이시스코스메틱 | Cosmetic composition for pore shrinkage and antioxidation containing mixed extract obtained using complex enzyme |
| KR20210110985A (en) * | 2020-03-02 | 2021-09-10 | 주식회사 코리아나화장품 | Cosmetic composition for preventing skin photo-aging comprising extract of castanea crenata or fractions from thereof as active ingredient |
| KR20210157328A (en) * | 2020-06-19 | 2021-12-28 | 고려대학교 산학협력단 | Cosmetic compositions comprising fermented chestnut inner shell extracts or its fractions as effective components |
| KR102350749B1 (en) * | 2020-08-31 | 2022-01-13 | 동의대학교 산학협력단 | Functional cosmetic composition with excellent skin anti-aging activity, skin moisturizing and skin soothing effect including fruit extract |
-
2023
- 2023-03-24 KR KR1020230038542A patent/KR102525091B1/en active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100955389B1 (en) * | 2009-06-29 | 2010-04-29 | (주)바이오에프디엔씨 | Cosmetic composition for pore-minimizing and inhibition of sebum secretion containing natural materials |
| KR20200040607A (en) * | 2018-10-10 | 2020-04-20 | 경북대학교 산학협력단 | Composition for anti-oxidation, anti-inflammation, anti-diabetes, pore shrink, or anti-wrinkle comprising extract of Summer prince apple |
| KR102110081B1 (en) * | 2019-07-29 | 2020-05-22 | (주)이시스코스메틱 | Cosmetic composition for pore shrinkage and antioxidation containing mixed extract obtained using complex enzyme |
| KR20210110985A (en) * | 2020-03-02 | 2021-09-10 | 주식회사 코리아나화장품 | Cosmetic composition for preventing skin photo-aging comprising extract of castanea crenata or fractions from thereof as active ingredient |
| KR20210157328A (en) * | 2020-06-19 | 2021-12-28 | 고려대학교 산학협력단 | Cosmetic compositions comprising fermented chestnut inner shell extracts or its fractions as effective components |
| KR102350749B1 (en) * | 2020-08-31 | 2022-01-13 | 동의대학교 산학협력단 | Functional cosmetic composition with excellent skin anti-aging activity, skin moisturizing and skin soothing effect including fruit extract |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101885195B1 (en) | Cosmetic Composition with Fermentative Extract of Osmanthus fragrans | |
| KR102373899B1 (en) | Multifunctional cosmetic composition containing complex natural extracts effective for skin wrinkle improvement, whitening, cell regeneration, and wound healing as an active ingredient | |
| KR101895412B1 (en) | A functional cosmetic composition for skin whitening comprising natural complex extract | |
| KR101860352B1 (en) | A cosmetic composition for treating demodex infestations comprising extract of artemisia apiaceae | |
| KR100954695B1 (en) | Cosmetic composition containing aspen active extract | |
| KR101855207B1 (en) | Cosmetic composition containing fermentative extract of terminalia ferdinandiana with increased amount of vitamin c fermented by aureobasidium pullulans | |
| KR101445642B1 (en) | Cosmetic composition comprising the extract of Lagerstroemia indica as active ingredient | |
| KR20150101810A (en) | Fermentative Extract of Hippophae rhamnoides with Increased Amount of Vitamin C Fermented by Aureobasidium pullulans and Cosmetic Composition containing the same | |
| KR20170055172A (en) | Cosmetic Composition Comprising Extracts of Centipeda minima | |
| KR102068736B1 (en) | A cosmetic composition for anti-aging comprising extract of coffee grounds | |
| KR102119511B1 (en) | Functional cosmetic composition | |
| KR101331227B1 (en) | Cosmetic composition comprising fermented extract of Ilex paraguayensis | |
| KR101843976B1 (en) | Cosmetic composition comprising extract of geminated phaseolus radiatus fermented by aureobasidium pullulans | |
| KR102525091B1 (en) | A cosmetic compositon for pore-minimizing comprising natural complex extract as an active ingredient | |
| KR102365027B1 (en) | Cosmetic composition for skin improvement comprising natural extracts and hampseed oil | |
| KR102455132B1 (en) | Cosmetic composition containing lemon myrtle extract and its manufacturing method | |
| KR101987425B1 (en) | A cosmetic composition comprising salix gracilistyla extract | |
| KR20180082058A (en) | A cosmetic composition for skin desquamation comprising natural complex extract | |
| KR102827796B1 (en) | Cosmetic composition for preventing skin aging comprising extract of citrus unshiu × citrus sinensis as active ingredient | |
| KR102335682B1 (en) | Cosmetic Composition For Moisturizing Skin Comprising Fermentative Extract of Equisetum giganteum | |
| KR102746298B1 (en) | A cosmetic composition comprising rucinol and natural extracts for skin-whitening | |
| KR101479244B1 (en) | Cosmetic composition comprising the extract of Lagerstroemia indica as active ingredient | |
| KR101479245B1 (en) | Cosmetic composition comprising the extract of Lagerstroemia indica as active ingredient | |
| KR100678865B1 (en) | Cosmetic composition for skin whitening containing upper limb extract and carnitine as active ingredients | |
| KR20230042925A (en) | Cosmetic composition for protecting skin comprising magnolia sieboldii extract fermented using bacillus subtilis j2k-351 starin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A302 | Request for accelerated examination | ||
| PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20230324 |
|
| PA0201 | Request for examination | ||
| PA0302 | Request for accelerated examination |
Patent event date: 20230324 Patent event code: PA03022R01D Comment text: Request for Accelerated Examination |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20230403 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20230418 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20230419 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20230419 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration |